Learn more about whether ACADIA Pharmaceuticals Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World. LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a lea ...
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using ...
Conroe-based bio-tech company VGXI Inc. has defaulted on its tax abatement agreement with Montgomery County and will pay more ...
Speculative activity surged across the micro-cap landscape during the third quarter, fueled by thematic momentum and outsized ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial ...
Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.
IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission ...
The U.S. Food and Drug Administration on Wednesday said it is aiming to reduce the number of human clinical studies required ...
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback